Indehaveren af markedsføringstilladelsen fremførte, at der er størst sandsynlighed for, at rabdomyolyse indtræffer i de første 6- 12 uger af terapien, og at korttidsdataene derfor er mest relevante.
Data from published clinical trials suggest that the risk of unconfirmed rhabdomyolysis (including cases in which increased CPK or muscle symptoms occur alone) with cerivastatin is similar to that of the other statins.